Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161170 | 0.92 | ACACB (0.39) | ACACBSOS1CRBNDDB1CYP3A4 | |
| SCHEMBL31161403 | 0.92 | ACACB (0.39) | ACACBSOS1CRBNDDB1CYP3A4 | |
| SCHEMBL31161718 | 0.90 | ACACB (0.41) | ACACBSOS1CRBNDDB1CYP3A4 | |
| SCHEMBL31161758 | 0.90 | ACACB (0.41) | ACACBSOS1CRBNDDB1CYP3A4 | |
| SCHEMBL31161675 | 0.90 | ACACB (0.41) | ACACBSOS1CRBNDDB1CYP3A4 | |
| SCHEMBL26509089 | 0.85 | MEN1 (0.46) | ACACBCRBNDDB1MEN1KMT2A | |
| SCHEMBL27123605 | 0.85 | SOS1 (0.43) | ACACBSOS1CRBNDDB1MEN1 | |
| SCHEMBL31161764 | 0.83 | CNR1 (0.37) | SOS1CRBNDDB1MEN1KMT2A | |
| SCHEMBL31161525 | 0.83 | CNR1 (0.36) | SOS1CRBNDDB1MEN1KMT2A | |
| SCHEMBL26101474 | 0.83 | ACACB (0.47) | ACACBCRBNDDB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | ACACB 1882/4885SOS1 595/4885CRBN 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.